MX9202944A - Formulacion de acetato de megesterol. - Google Patents

Formulacion de acetato de megesterol.

Info

Publication number
MX9202944A
MX9202944A MX9202944A MX9202944A MX9202944A MX 9202944 A MX9202944 A MX 9202944A MX 9202944 A MX9202944 A MX 9202944A MX 9202944 A MX9202944 A MX 9202944A MX 9202944 A MX9202944 A MX 9202944A
Authority
MX
Mexico
Prior art keywords
concentration
percent
acetate formulation
megestrol acetate
megesterol acetate
Prior art date
Application number
MX9202944A
Other languages
English (en)
Spanish (es)
Inventor
Anne E Atzinger
Robert J Bequette
Robert E Davis
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX9202944A publication Critical patent/MX9202944A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
MX9202944A 1991-06-18 1992-06-17 Formulacion de acetato de megesterol. MX9202944A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71715591A 1991-06-18 1991-06-18

Publications (1)

Publication Number Publication Date
MX9202944A true MX9202944A (es) 1993-07-01

Family

ID=24880926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9202944A MX9202944A (es) 1991-06-18 1992-06-17 Formulacion de acetato de megesterol.

Country Status (22)

Country Link
US (1) US5338732A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0519351B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3450356B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100211192B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1038904C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE142882T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU647933B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2071141A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ289620B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69213836T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0519351T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2091977T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI101602B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3021072T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1005017A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU213511B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE77167B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL102198A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9202944A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK281841B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW211520B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA924282B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698562A (en) * 1991-10-08 1997-12-16 Ascent Pediatrics, Inc. Palatable trimethoprim oral solution
US5563177A (en) * 1995-01-30 1996-10-08 American Home Products Corporation Taste masking guaifenesin containing liquids
US6028065A (en) * 1998-04-20 2000-02-22 Pharmaceutical Resources, Inc. Flocculated suspension of megestrol acetate
US6268356B1 (en) 1998-04-20 2001-07-31 Pharmaceutical Resources, Inc. Flocculated suspension of megestrol acetate
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030198679A1 (en) * 2000-11-08 2003-10-23 Kundu Subhas C. Flocculated pharmaceutical suspensions and methods for actives
PT1275377E (pt) * 2001-07-11 2003-11-28 Fidia Farmaceutici Granulados contendo substancias lipossoluveis e sua preparacao
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
EP2263650A3 (en) * 2002-04-12 2013-12-25 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
KR100841082B1 (ko) 2006-08-23 2008-06-24 대원제약주식회사 메게스트롤 아세테이트의 서상화된 현탁제
KR20080035374A (ko) * 2006-10-19 2008-04-23 주식회사 엘지생명과학 약제학적으로 안정한 메게스트롤 물질의 현탁액제
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CA2676010C (en) * 2007-01-19 2016-05-17 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US20100137424A1 (en) * 2007-01-22 2010-06-03 Mostafa Akbarieh Pharmaceutical compositions comprising nebivolol or a nebivolol analogue
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
KR101279568B1 (ko) * 2010-12-10 2013-07-15 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 메게스트롤 아세테이트를 포함하는 경구용 약학 조성물
US9974850B2 (en) * 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
CN113274351B (zh) * 2020-02-20 2024-04-12 东曜药业有限公司 一种口服醋酸甲地孕酮混悬液及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB870286A (en) * 1958-11-04 1961-06-14 British Drug Houses Ltd Improvements in or relating to 6-methyl-3-oxo-í~-steroid compounds
FR2290906A1 (fr) * 1974-11-13 1976-06-11 Dick Pierre Nouvelles associations hormonales synergisees pour l'implantation d'animaux de boucherie
US4370321A (en) * 1976-09-01 1983-01-25 Mead Johnson And Company Progestational adjuvant therapy
US4402695A (en) * 1980-01-21 1983-09-06 Alza Corporation Device for delivering agent in vagina
US4396615A (en) * 1981-06-24 1983-08-02 Duke University Method of treating androgen-related disorders
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4782047A (en) * 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration

Also Published As

Publication number Publication date
KR100211192B1 (ko) 1999-07-15
FI101602B1 (fi) 1998-07-31
EP0519351A3 (en) 1993-03-10
IL102198A0 (en) 1993-01-14
HU213511B (en) 1997-07-28
HUT61471A (en) 1993-01-28
IE77167B1 (en) 1997-12-03
DK0519351T3 (da) 1996-10-07
CZ185392A3 (en) 1993-01-13
GR3021072T3 (en) 1996-12-31
CN1067580A (zh) 1993-01-06
JP3450356B2 (ja) 2003-09-22
CZ289620B6 (cs) 2002-03-13
KR930019203A (ko) 1993-10-18
US5338732A (en) 1994-08-16
IE921958A1 (en) 1992-12-30
ZA924282B (en) 1993-02-24
SK185392A3 (en) 1995-11-08
FI922764A0 (fi) 1992-06-15
ES2091977T3 (es) 1996-11-16
FI922764L (fi) 1992-12-19
EP0519351B1 (en) 1996-09-18
FI101602B (fi) 1998-07-31
CA2071141A1 (en) 1992-12-19
AU647933B2 (en) 1994-03-31
AU1828192A (en) 1992-12-24
DE69213836D1 (de) 1996-10-24
IL102198A (en) 1996-07-23
CN1038904C (zh) 1998-07-01
EP0519351A2 (en) 1992-12-23
JPH05186351A (ja) 1993-07-27
ATE142882T1 (de) 1996-10-15
TW211520B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-08-21
HK1005017A1 (en) 1998-12-18
SK281841B6 (sk) 2001-08-06
HU9202029D0 (en) 1992-09-28
DE69213836T2 (de) 1997-04-30

Similar Documents

Publication Publication Date Title
MX9202944A (es) Formulacion de acetato de megesterol.
FI88459B (fi) Foerfarande foer framstaellning av en foer intranasal applikation laemplig steroidkomposition
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
FI956228A0 (fi) Sisäänhengitykseen tarkoitettuja koostumuksia
BR9705484A (pt) Composições de zinco com sabor para uso oral incorporando cobre
ES2099438T3 (es) Polvo seco y estable de cefalosporina hidratada para formulacion de suspension oral.
IT1243859B (it) Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids.
SE8001686L (sv) Tuggummi
IL83086A0 (en) Stable,injectable solutions of vinca dimer salts
US5352681A (en) Pharmaceutical enema preparation
EP0302836B1 (en) Pharmaceutical compositions for topical use containing miocamycin
CA2078885A1 (en) Pharmaceutical compositions containing amethocaine
ATE145333T1 (de) Hirudin enthaltende orale arzneimittel
ITMI913510A1 (it) Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
ES2094566T3 (es) Nuevas formulaciones farmaceuticas de espiramicina.
GB9202993D0 (en) Novel pharmaceutical uses of bilobalide and derivatives thereof and pharmaceutical compositions adapted for such use
RU1839099C (ru) Станок дл нат гивани струн теннисных ракеток
ES2159088T3 (es) Composiciones antiacidas liquidas.
MX9601756A (es) Composicion liquida estable que contiene urato-oxidasa, y composicion liofilizada para su preparacion.
ATE181828T1 (de) Oral anzuwendendes arzneimittel bestehend aus ibuprofen